ImmunoGen 過去の業績

過去基準チェック /06

ImmunoGenの収益は年間平均-5%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19% 23.3%割合で増加しています。

主要情報

-5.0%

収益成長率

12.9%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	23.3%
株主資本利益率	-13.1%
ネット・マージン	-25.6%
前回の決算情報	30 Sep 2023

Recent updates

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

Feb 09

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Jan 09

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Dec 22

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Oct 20

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

Aug 06

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Jul 20

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

May 03

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

Apr 18

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Feb 25

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

Jan 03

収支内訳

ImmunoGen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:IMGN 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
30 Sep 23	288	-74	156
30 Jun 23	190	-180	152
31 Mar 23	121	-240	139
31 Dec 22	109	-223	116
30 Sep 22	96	-201	88
30 Jun 22	89	-161	64
31 Mar 22	92	-129	50
31 Dec 21	70	-139	44
30 Sep 21	128	-71	40
30 Jun 21	137	-56	40
31 Mar 21	135	-49	40
31 Dec 20	132	-44	39
30 Sep 20	91	-71	39
30 Jun 20	86	-70	38
31 Mar 20	87	-89	37
31 Dec 19	82	-104	38
30 Sep 19	51	-151	38
30 Jun 19	48	-176	38
31 Mar 19	42	-174	38
31 Dec 18	53	-169	37
30 Sep 18	79	-140	36
30 Jun 18	77	-150	36
31 Mar 18	107	-117	36
31 Dec 17	115	-96	34
30 Sep 17	90	-117	33
30 Jun 17	89	-105	35
31 Mar 17	57	-142	35
31 Dec 16	49	-157	39
30 Sep 16	53	-156	38
30 Jun 16	60	-145	34
31 Mar 16	65	-129	35
31 Dec 15	57	-119	31
30 Sep 15	87	-72	29
30 Jun 15	86	-61	28
31 Mar 15	79	-57	27
31 Dec 14	74	-73	26
30 Sep 14	56	-82	25
30 Jun 14	60	-71	24
31 Mar 14	58	-67	23
31 Dec 13	76	-31	22
30 Sep 13	49	-59	22
30 Jun 13	36	-73	21
31 Mar 13	35	-73	27

質の高い収益: IMGNは現在利益が出ていません。

利益率の向上: IMGNは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: IMGNは利益が出ておらず、過去 5 年間で損失は年間5%の割合で増加しています。

成長の加速: IMGNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IMGNは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。

株主資本利益率

高いROE: IMGNは現在利益が出ていないため、自己資本利益率 ( -13.09% ) はマイナスです。

ImmunoGen 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means

President notifies of intention to sell stock

Insider notifies of intention to sell stock

ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price

Forecast breakeven date pushed back to 2024

There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump

Insider notifies of intention to sell stock

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Insider exercised options and sold US$3.0m worth of stock

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

New major risk - Share price stability

Price target increased by 10% to US$25.39

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold US$1.5m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely

Insider exercised options and sold US$1.9m worth of stock

Insider recently sold US$1.3m worth of stock

ImmunoGen, Inc. Announces Executive Changes

Insider notifies of intention to sell stock

Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts

President recently sold US$17m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.0% to US$19.00

Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?

Price target increased by 13% to US$16.20

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

Consensus revenue estimates increase by 80%

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Price target increased by 18% to US$14.10

Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss, revenue downgraded

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06